Immunovia AB (0G8X) AI Stock Analysis

Immunovia AB

(LSE:0G8X)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Clinical ValidationThe reported sensitivity and specificity provide meaningful clinical support for PancreaSure’s early-detection proposition. This evidence can strengthen regulatory, reimbursement, and provider discussions, while improving the company’s ability to convert clinical credibility into broader adoption over the next several quarters.

Negative Factors

Cash Runway RiskThe limited cash runway creates a durable execution risk because commercialization, clinical studies, and reimbursement efforts must continue before the business reaches self-sustaining scale. Dependence on equity, partnerships, or other capital could constrain strategy and increase funding pressure.

Immunovia AB (0G8X) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: SEK 6.73M
Dividend Yield: ―
Average Volume (3M): 236.52K
Price to Earnings (P/E): -0.3
Beta (1Y): 1.09
Revenue Growth: 31.66%
EPS Growth: 79.68%
Country: UK
Employees: 18
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Immunovia AB Business Overview & Revenue Model

Company Description

Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic...

Immunovia AB Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:-60.67%|Next Earnings Date:Nov 01, 2026

Earnings Call SentimentNeutral

The call presents a mix of meaningful commercial and clinical progress alongside material operational and financing risks. Key positives include very strong percentage revenue growth, robust clinical performance (83.3% sensitivity, ~92% specificity), major center uptake, and an expanding engaged pipeline. Offsetting these are still-modest absolute revenues, an increased operating loss due to higher personnel and study spending, limited cash runway into Q4 2026 requiring near-term financing or partnerships, and uncertainty around reimbursement levels and timing. Overall, the company is showing clear early commercial and clinical traction but remains exposed to execution and funding risks as it scales.

Positive Updates

Strong YoY Revenue Growth

Net sales increased to SEK 381,000 in Q2 2026 from SEK 90,000 in Q2 2025, a >300% year-over-year increase. For the first six months, net sales rose to SEK 755,000 from SEK 229,000, an approximately 230% increase year-over-year.

Negative Updates

Limited Absolute Revenue Base

Despite very strong percentage growth, absolute Q2 revenue remains small at SEK 381,000 and SEK 755,000 for the first six months, meaning revenue contribution is still nascent and not yet offsetting operating costs.

Company Guidance

Guidance highlights: Immunovia plans to submit for Medicare coverage in Q3 2026 and expects a New York decision in Q3, while transitioning to the volume‑building phase after the Sept 2025 launch (27 high‑risk surveillance programs have used PancreaSure, >110 engaged prospects vs 71 prior, including 10 of the top 20 cancer centers). Q2 net sales were SEK 381,000 (up >300% YoY from SEK 90,000), H1 sales SEK 755,000 (vs SEK 229,000), Q2 operating loss SEK 22.9m (H1 SEK 41.3m), Q2 net loss SEK 22.8m (EPS -SEK 0.03 vs -0.14), average cash burn ~SEK 7m/month (below prior guidance SEK 8–10m), cash SEK 34.9m (runway into Q4 2026) with plans to extend runway into 2H 2027 via financing/partnerships. Clinical pooled performance in the symptomatic high‑risk subgroup: sensitivity 83.3% and specificity ~92%; insurer submissions began Feb 2026; DECIDE completes data collection in Aug, patient survey results due this month, Kaiser pre‑diagnostic analysis in Q3 with results in Q4, and ~15 sites planned for the ASSURE registry.

Immunovia AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0G8X against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:DVYSR	62Neutral	SEK 928.94M	59.78	―	―	6.51%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:QLINEA	43Neutral	SEK 282.34M	-1.13	-48.10%	―	33.26%	90.73%
SE:BIOVIC.B	41Neutral	SEK 103.68M	-1.44	-75.51%	―	56.06%	63.95%
SE:ACARIX	40Underperform	SEK 223.04M	-5.29	-100.09%	―	65.82%	41.28%

* Healthcare Sector Average

Performance Comparison

GB:0G8X and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0G8X	Immunovia AB	0.07	-0.25	-78.06%
SE:QLINEA	Q-linea AB	14.90	-10.30	-40.87%
SE:ACARIX	Acarix AB	0.18	-0.10	-35.61%
SE:BIOVIC.B	Biovica International AB Class B	0.36	-0.14	-27.47%
SE:DVYSR	Devyser Diagnostics AB	55.00	-68.00	-55.28%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Immunovia AB AI Stock Analysis